254,290 Shares in Pfizer Inc. (NYSE:PFE) Acquired by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP acquired a new position in shares of Pfizer Inc. (NYSE:PFE) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 254,290 shares of the biopharmaceutical company’s stock, valued at approximately $7,057,000.

A number of other institutional investors also recently added to or reduced their stakes in PFE. Intech Investment Management LLC raised its stake in Pfizer by 9.3% in the first quarter. Intech Investment Management LLC now owns 556,939 shares of the biopharmaceutical company’s stock valued at $15,455,000 after buying an additional 47,451 shares in the last quarter. Nicolet Advisory Services LLC grew its stake in shares of Pfizer by 9.4% in the 1st quarter. Nicolet Advisory Services LLC now owns 34,431 shares of the biopharmaceutical company’s stock valued at $922,000 after purchasing an additional 2,951 shares during the last quarter. Jupiter Asset Management Ltd. acquired a new stake in shares of Pfizer during the first quarter worth $3,221,000. PARK CIRCLE Co raised its position in Pfizer by 186.8% during the 1st quarter. PARK CIRCLE Co now owns 26,100 shares of the biopharmaceutical company’s stock worth $724,000 after buying an additional 17,000 shares during the last quarter. Finally, Te Ahumairangi Investment Management Ltd raised its position in Pfizer by 7.1% during the 1st quarter. Te Ahumairangi Investment Management Ltd now owns 214,114 shares of the biopharmaceutical company’s stock worth $5,942,000 after buying an additional 14,190 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent analyst reports. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Barclays increased their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, July 10th. Finally, Morgan Stanley upped their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $34.50.

Pfizer Trading Up 0.9 %

NYSE:PFE traded up $0.26 during trading hours on Friday, reaching $29.97. 30,021,169 shares of the company were exchanged, compared to its average volume of 30,277,082. The firm has a market cap of $169.83 billion, a price-to-earnings ratio of -499.42, a PEG ratio of 1.17 and a beta of 0.69. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The stock has a 50 day simple moving average of $28.40 and a 200 day simple moving average of $27.74. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $37.80.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.23 earnings per share. As a group, analysts predict that Pfizer Inc. will post 2.39 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date is Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.61%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.